{'fraction_non_alphanumeric': 0.03861788617886179, 'fraction_numerical': 0.01016260162601626, 'mean_word_length': 5.7534246575342465, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The adverse events profile of anti‐IGF‐1R monoclonal antibodies in cancer therapy

Insulin‐like growth factor‐1 receptor (IGF‐1R) targeted therapies have become one of the intriguing areas in anticancer drug development during the last decade. As one of these therapies, anti‐IGF‐1R monoclonal antibodies (mAbs) are also advancing further in development. Our purpose was to conduct a systematic review of the adverse events (AEs) caused by anti‐IGF‐1R monoclonal antibodies in cancer therapy.